Agios Pharmaceuticals, Inc. reported $98M of revenue over the trailing twelve months, +141% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $98M (to Q2 2026). Net income: −$411M, trailing twelve months to Q2 2026. Free cash flow: −$365M, trailing twelve months to Q2 2026. Operating margin: −573%, trailing twelve months to Q2 2026.

AGIOAgios Pharmaceuticals, Inc.

Healthcare

$31.83-16% 1Y

$31.83

$22.3452 weeks$45.49

AGIO as reported

Agios Pharmaceuticals, Inc. reported $98M of revenue over the trailing twelve months, +141% on the year before. 9 reported series are charted on this page, each one as filed.

$98M

Revenue, trailing twelve months · to Q2 2026 · +141% against the twelve months before

Net income: −$411M
Net income · −163% year on year · trailing twelve months to Q2 2026
Free cash flow: −$365M
Free cash flow · −11% year on year · trailing twelve months to Q2 2026
Operating margin: −573%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AGIO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$98M	+141%	Q2 2026
Net income	−$411M	−163%	Q2 2026
EPS	−$7.01	−164%	Q2 2026
Gross margin	91%	n/a	Q2 2026
Operating margin	−573%	n/a	Q2 2026
Net margin	−512%	n/a	Q2 2026
ROE	−36%	n/a	Q2 2026
ROA	−33%	n/a	Q2 2026
Free cash flow	−$365M	−11%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.